Prophylaxe der kaninen Parvovirose. Teil 2: Impfstoffe

Bergmann, Michele; Freisl, Monika und Hartmann, Katrin (2021): Prophylaxe der kaninen Parvovirose. Teil 2: Impfstoffe. In: Tierärztliche Praxis Ausgabe Kleintiere Heimtiere, Bd. 49, Nr. 2: S. 122-128

Abstract

Vaccination is still the most effective measure to prevent canine parvovirosis. Therefore, vaccines against canine parvovirus (CPV) infection are considered core vaccines. Modified life vaccines (MLV) have been proven to be very effective and safe, since they are characterized by early onset (within a few days after vaccination) and long duration of immunity (several years). MLV do not contain adjuvants;they are also advantageous in terms of possessing less allergenic and toxic properties. Therefore, MLV are widely used as first line vaccines. In Germany and in most other European countries, only MLV are available on the market. MLV contain CPV-2 or (less often) CPV-2b and offer cross-protection against the variants CPV-2a, -2b, -2c that are relevant for dogs in the field. Revaccination with MLV should be performed in 3-year-intervals or longer intervals (only in case of lacking antibodies) even if the licensed MLV is registered for re-vaccination intervals of 1 or 2 years. MLV should only be administered to healthy dogs older than 4 to 6 weeks of age. A possible disadvantage of MLV is its interference with the diagnosis of a CPV infection.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Tiermedizin > Zentrum für Klinische Tiermedizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1434-1239
• Sprache: Deutsch